TY - JOUR
T1 - Metastatic tumor-in-A-Dish, a novel multicellular organoid to study lung colonization and predict therapeutic response
AU - Ramamoorthy, Prabhu
AU - Thomas, Sufi Mary
AU - Kaushik, Gaurav
AU - Subramaniam, Dharmalingam
AU - Chastain, Katherine M.
AU - Dhar, Animesh
AU - Tawfik, Ossama
AU - Kasi, Anup
AU - Sun, Weijing
AU - Ramalingam, Satish
AU - Gunewardena, Sumedha
AU - Umar, Shahid
AU - Mammen, Joshua M.
AU - Padhye, Subhash B.
AU - Weir, Scott J.
AU - Jensen, Roy A.
AU - Sitta Sittampalam, G.
AU - Anant, Shrikant
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Metastasis is a major cause of cancer-related deaths. A dearth of preclinical models that recapitulate the metastatic microenvironment has impeded the development of therapeutic agents that are effective against metastatic disease. Because the majority of solid tumors metastasize to the lung, we developed a multicellular lung organoid that mimics the lung microenvironment with air sac-like structures and production of lung surfactant protein. We used these cultures, called primitive lung-in-a-dish (PLiD), to recreate metastatic disease using primary and established cancer cells. The metastatic tumor-in-a-dish (mTiD) cultures resemble the architecture of metastatic tumors in the lung, including angiogenesis. Pretreating PLiD with tumor exosomes enhanced cancer cell colonization. We next tested the response of primary and established cancer cells to current chemotherapeutic agents and an anti-VEGF antibody in mTiD against cancer cells in two-dimensional (2D) or 3D cultures. The response of primary patient-derived colon and ovarian tumor cells to therapy in mTiD cultures matched the response of the patient in the clinic, but not in 2D or single-cell-type 3D cultures. The sensitive mTiD cultures also produced significantly lower circulating markers for cancer similar to that seen in patients who responded to therapy. Thus, we have developed a novel method for lung colonization in vitro, a final stage in tumor metastasis. Moreover, the technique has significant utility in precision/personalized medicine, wherein this phenotypic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent, thereby increasing the probability of response to treatment while reducing unnecessary side effects. Significance: A lung organoid that exhibits characteristics of a normal human lung is developed to study the biology of metastatic disease and therapeutic intervention.
AB - Metastasis is a major cause of cancer-related deaths. A dearth of preclinical models that recapitulate the metastatic microenvironment has impeded the development of therapeutic agents that are effective against metastatic disease. Because the majority of solid tumors metastasize to the lung, we developed a multicellular lung organoid that mimics the lung microenvironment with air sac-like structures and production of lung surfactant protein. We used these cultures, called primitive lung-in-a-dish (PLiD), to recreate metastatic disease using primary and established cancer cells. The metastatic tumor-in-a-dish (mTiD) cultures resemble the architecture of metastatic tumors in the lung, including angiogenesis. Pretreating PLiD with tumor exosomes enhanced cancer cell colonization. We next tested the response of primary and established cancer cells to current chemotherapeutic agents and an anti-VEGF antibody in mTiD against cancer cells in two-dimensional (2D) or 3D cultures. The response of primary patient-derived colon and ovarian tumor cells to therapy in mTiD cultures matched the response of the patient in the clinic, but not in 2D or single-cell-type 3D cultures. The sensitive mTiD cultures also produced significantly lower circulating markers for cancer similar to that seen in patients who responded to therapy. Thus, we have developed a novel method for lung colonization in vitro, a final stage in tumor metastasis. Moreover, the technique has significant utility in precision/personalized medicine, wherein this phenotypic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent, thereby increasing the probability of response to treatment while reducing unnecessary side effects. Significance: A lung organoid that exhibits characteristics of a normal human lung is developed to study the biology of metastatic disease and therapeutic intervention.
UR - http://www.scopus.com/inward/record.url?scp=85064201927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064201927&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-18-2602
DO - 10.1158/0008-5472.CAN-18-2602
M3 - Article
C2 - 30674533
AN - SCOPUS:85064201927
SN - 0008-5472
VL - 79
SP - 1681
EP - 1695
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -